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Enhancement of anti-tumour immunity in syngeneic mice after MHC class
II gene transfection
C Mongini, M S'anchez Lockhart, CI Waldner, EMC Alvarez, MJ Gravisaco, MI Roig and SE
Hajos
Catedra de Immunologia, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Summary The relationship between tumorigenicity and expression of MHC class II molecules in a class II-
negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC
class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and
LBC cell line, digested with EcoRI, BamHI and HindlIl and hybridised with specific probes for I-Acd and I-
Aftd chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment
with IFN-y (20- 1000 IU ml-') failed to induce the expression of MHC class II antigens in LBC cell line. LBC
cells were tri-transfected by a liposome-mediated protocol with I-Aocd, I-Afd genes and pSV2neo. Cells were
selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-
A' clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 103 LBCT (I-A+)
cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 106 LBCT cells was three times
the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was
significantly enhanced upon priming with irradiated LBC-transfected cells (27+2%) compared with irradiated
LBC cells (15+ 1.5%) in a 4 h 5'Cr-release assay. It is suggested that neoexpression of MHC class II molecules
enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs),
which may be used to improve tumour-specific immunity in the autologous host.
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The term immunosurveillance has been used to describe the
concept of natural immunological host resistance against the
development of cancer. According to Burnet's theory,
primary immune system function is to recognise and destroy
neoplastic cells before they grow and develop into a
perceptible tumour (Burnet, 1970).
Tumour cells which display immunogenic epitopes may
evade immune detection by lacking the appropriate restric-
tion components (Hammerling et al., 1987). Cytotoxic T cells
can recognise intracellular peptide antigens brought to the
cell surface in conjunction with major histocompatibility
complex (MHC) proteins (Tanaka et al., 1988). As T cells
recognise tumour-associated antigens in the context of MHC
class I and II molecules, the ability to elicit an anti-tumour
response is dependent not only on the presence of tumour-
associated antigens but also on an appropriate presentation
of these molecules (loannides and Whiteside, 1983; Kem et
al., 1986). The expression of MHC proteins on tumour cells
may be critical for immunological recognition and tumour
destruction.
The expression of MHC class II molecules on cells confers
on them the ability to act as antigen presenting cells. In some
autoimmune diseases, the abnormal expression of class II
molecules allows the presentation of self antigens triggering
an immune response directly against the aberrant tissue. This
is the case for pancreatic fl-cells in certain types of diabetes
(Bottazo et al., 1985) or for follicular cells in autoimmune
thyroiditis (Londei et al., 1984). On the other hand, it has
been demonstrated that an enhanced expression of class II
molecules in the cells of a murine L1210 lymphoma
subpopulation likewise correlated with an increase in
immunogenicity and decrease in tumorigenicity (Fuji and
Iribe, 1986).
Transfection of MHC genes has been used to study the
effect on tumour cell growth in vivo as well as to induce a
protective immune response against the tumour itself
(Ostrand-Rosemberg et al., 1990; James et al., 1991).
Therefore, by inducing neoexpression of MHC class II
antigens on neoplastic cells, antigen presentation could be
enhanced thus improving anti-tumour immunity in syngeneic
hosts.
In previous work we have reported the establishment and
characterisation of the LBC cell line (Mongini et al., 1991)
derived from the original T-cell leukaemia LB (Ruggiero et
al., 1984). LBC cells express the following surface markers:
Thy-1, Lyt-2 (CD 8), CD 41ow+ CD 25 (IL-2 receptor, a
chain), class I (Kd and Dd), but not class II (I-Ad, I-Ed) gene
products. Although this cell line is tumorigenic in syngeneic
mice, survival rate ofmice inoculated with LBC cells is higher
when compared with that of mice inoculated with LB cells.
Furthermore, when compared with the original non-
immunogenic leukaemic cells, LBC induce a weak immune
response in their syngeneic host (Mongini et al., 1995).
Taking these findings into account and having demon-
strated that LBC cells lack MHC class II antigens, grow
aggressively in syngeneic hosts killing the animals in a
relatively short time and induce a weak immune response,
these cells provide a useful model for studying the relation-
ships of class II molecules expression, immunogenicity and
tumour development inter se.
Materials and methods
Mice
Two to four month old normal BALB/c mice were raised in
the animal colony of the National Academy of Medicine,
Buenos Aires, Argentina, and maintained on Cargill pellets
and water ad libitum.
Tumour
LB is a T-cell leukaemia, which spontaneously arose in a
BALB/c mouse and has been maintained by serial passages in
the peritoneal cavity of syngeneic hosts (Ruggiero et al.,
1984; Alvarez et al., 1989; Lugasi et al., 1990). LBC is an
established cell line derived from LB leukaemia (Mongini et
al., 1991). It was maintained in RPMI-1640 (Gibco, Grand
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January 1996Island, New York, USA) supplemented with 10% heat
inactivated FCS, 2 mM L-glutamine, 20 mM Hepes buffer,
100 jg ml-' penicillin, 150 ,ig ml-' streptomycin and 50 jgM
2-mercaptoethanol. Cells were used between passages 120 and
140.
Induction of MHC molecules by treatment with IFNs
LBC cells (3 x 106 ml-') were incubated for 72 h at 37°C
either with 20-1000 IU ml-' of IFNy (Genzyme, USA) or
20-1000 IU ml-' of IFNa+ / (Genzyme, USA) and expres-
sion of MHC class II molecules analysed by ELISA.
Cell ELISA
This was carried out by the method described previously
(Mongini et al., 1995) using 96-well flat bottom microtitre
plates (NUNC, Denmark). Briefly, 3 x 10' LBC cells, LBC-
transfected cells (LBCT) or macrophages were seeded into the
wells and blocked with 1.5% BSA in TBS buffer (150 mM
sodium chloride, 20 mM Tris-HCl; pH 7.4), centrifuged and
the supernatant discarded. Cells were fixed with freshly
prepared glutaraldehyde (0.25% in TBS) and neutralised with
100 mM glycine- 1% BSA. Biotinylated monoclonal antibody
clone 39- 10-8 (specific for I-Ad molecules, Pharmingen) was
added and incubated at 37°C for 1 h. Avidin-phosphatase-
conjugated (Biosys, Institute Pasteur, Paris) was used and the
reaction developed by addition of freshly prepared p-
nitrophenylphosphate substrate (Sigma Chemical, St Louis,
MO, USA). The reaction was stopped with 5 N sodium
hydroxide and read for optical density at 405 nm in an
automated ELISA reader (Dynatech, Denmark). Background
absorbance was determined in control wells not treated with
the first antibody but which had all the other reagents.
Flow cytometry
LBC and LBC transfected cell suspensions (1.5 x 106) were
washed in Hanks' solution containing 1% BSA and 0.1%
sodium azide. Cells were stained with monoclonal antibody
MKD6, specific for I-Ad (Kappler et al., 1981) or with a
control isotyping antibody at 4°C for 30 min and, after
washing, a second FITC-conjugated antibody was added and
cells were left for an additional 30 min at 4°C. Cells were
washed, fixed in paraformaldehyde and analysed by flow
cytometry on a Becton Dickinson FACScan.
Isolation of eukaryotic DNA and DNA blot hybridisation
DNA was isolated from LB, LBC and normal BALB/c
splenocytes according to the method described by Gross-
Bellard et al. (1973) with slight modifications. Digested DNA
(10 jg) was electrophoresed through a 1% agarose gel and
transferred to nylon membrane as described previously
(Sambrook et al., 1989). Hybridisation was carried out for
24 h at 60°C in 4xSSPE, 1% SDS, 0.001% PPi,
0.01 mg ml-' polyanetosulphonic acid (Sigma) and
100 jug ml-' denatured salmon sperm (Sigma) supplemented
with random oligo-primed 32P-labelled probes specific for I-
Aod and I-Afld antigens. These probes were kindly provided
by L Hood (Steinmetz et al., 1982, 1984). Filters were washed
twice at room temperature with 2 x SSC containing 0.5%
SDS and twice at 60°C with 0.1 x SSC containing 0.5% SDS.
Filters were exposed for 24-48 h at -70°C and developed.
DNA transfection
LBC cells were tri-transfected using Lipofectin according to
the procedure described by Dorman (Dorman, 1989),
employing pSV2.neo vector DNA, I-Aoad and I-Afld genes
and selected by growth in medium containing the neomycin
analogue G418. Briefly, 2 x 107 LBC cells were co-transfected
with 1 jig of pVS2.neo and 10 jig each of I-Acxd and I-Afld
constructs (Steinmetz et al., 1982, 1984) in a 100 jg of
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Lipofectin in FCS-free medium solution. Transfectants were
selected by growth in medium supplemented with
800 jug ml-1 G418 and resulting clones screened by cell
ELISA. The highest I-A-expressing clone, assessed by cell
ELISA and by FACS, named LBCT, was analysed for its
biological behaviour and in vivo experiments. Control cells
were obtained by transfection of pVS2.neo alone.
Generation ofspecific anti-tumour cytotoxic cells
Groups of six normal BALB/c mice were inoculated
subcutaneously with 106 LBCi cells per mouse or LBCTi
cells per mouse (LBC or LBCT cells irradiated with 3000
rads) on days 1, 7 and 14. These mice were injected in the
base of the tail with 1 x 106 viable LBCi or LBCTi cells a
week before the reaction was performed, while 2 x 106 spleen
cells ml-1 from normal or immunised BALB/c mice were
cultured in RPMI medium for 5 days at 37°C and 4% carbon
dioxide in air. Harvested cells were used as effector cells in a
51Cr-release assay (Coligan et al., 1992).
51Chromium-release assay
Approximately 1.0 x 107 tumour target cells were labelled with
100 4uCi 51Cr (Na25' CrO4, Du Pont, NEN Products, Boston,
MA, USA). After incubating at 37°C for 45 min, cells were
washed three times and plated at 1.0 x 104 cells 100 1ld-1 per
well in 96-well round-bottomed culture plates. Effectors were
added at various concentrations, in triplicate, and incubated
for 4 h at 37°C. Plates were centrifuged at 200 g for 5 min and
100 Ml of cell-free supernatant was harvested from each well
and radioactivity determined on a gamma scintillation counter
(Alfatron, Buenos Aires). Spontaneous release and maximum
release were determined by incubating target cells in medium
or in a 2% NP-40 solution respectively. Percentage of specific
lysis was calculated as follows:
(experimental release-spontaneous release)
100 x
(maximum release-spontaneous release)
Positive controls were generated by co-culturing spleen
cells (4.8 x 106 cells per well) obtained from BALB/c mice
primed with LBCi or LBCTi cells and irradiated Swiss
splenocytes (2.4 x 106 cells per well), in a 24-well culture plate.
Effector cells were harvested on day 5 and tested against
Swiss blast targets in a 4 h 5"Cr-release assay. A cytotoxicity
of 10% or more was invariably statistically significant at P <
0.05 and was considered as being positive.
Tumour challenge experiments
BALB/c mice were challenged with 1.0 x 106 or 1.0 x 103
viable LBCT and LBC cells. The mortality rate caused by
tumour growth was recorded and differences were considered
statistically significant at P < 0.05, by log-rank test (Peto et
al., 1977). DT50 represented the time at which 50% of
challenged mice had died (Mongini et al., 1995).
Statistical analysis
All determinations were done in triplicate and statistical
significance was established by Student's t-test for indepen-
dent samples. Survival times were analysed with log-rank test
(Peto et al., 1977). Differences were considered statistically
significant for P < 0.05.
Results
Southern blot analysis of LB and LBC cells
To determine whether LB and LBC cells carry the accurate
genetic information for the synthesis of MHC class II
molecules (I-Ad), DNA was isolated from LB, LBC andMHC gene transfection and anti-tumour immunity
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normal splenocytes, digested with BamHI, HindIII, EcoRI
and analysed by Southern blot (Figure 1). Hybridisation with
probes specific for I-Aad and I-A#d genes showed no
alterations in LB or LBC cells as compared with controls
(normal BALB/c splenocytes).
Induction ofI-Ad expression on LBC cells by either IFN-a+ /
or IFN-y treatments
In order to determine the possibility that IFN treatments
could activate I-Ad expression on tumour cells, LBC cells
were incubated with different concentrations of IFN-
a+,/ or IFN-y (20-1000 IU ml-') and the presence of
such molecules was tested by cell ELISA. As Figure 2
shows, it was not possible to induce I-Ad expression after
treatment either with IFN-a+,B or IFN-y. However, I-Ad
antigens were enhanced on normal macrophages used as
controls.
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I-Ad gene transfer and expression of LBC cell line
Neoexpression of I-Ad molecules was accomplished by
transforming LBC cells by liposome-mediated gene transfer
and selection with the antibiotic G418. Three clones with
different degrees of I-Ad expression were obtained from the
original LBC cell population. The clone expressing the
highest level of I-Ad antigens analysed by cell ELISA and
FACS (Figures 3* and 4b) named hereafter LBCT, was
chosen for further experiments designed to evaluate the role
of I-Ad molecules in oncogenesis and host resistance.
Effect of I-Ad molecules on tumorigenic properties
In order to study whether the expression of MHC class II
molecules could have any effect on tumour growth, groups of
12 BALB/c mice were inoculated i.p. with 1 x 106 or 1 x 103
LBCT cells per mouse. Although in vitro LBCT cells had
E
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Figure 2 Induction of I-Ad expression on LBC cells by either
IFN a +,B or IFNy treatments. LBC cells (3 x 106) were incubated
for 72h at 37°C either with 20-1000IUml-1 or IFN-y or 20-
1000 IUml- of IFN a +f, and expression of MHC class II
molecules was analysed by ELISA as described in Materials and
methods. Positive controls were performed by incubating
macrophages with 1000IUml-1. Results are shown as OD at
405nm and represent the mean value +s.d. triplicates. LI, LB
cells; _, LBC cells; EZ, macrophages.
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Figure 1 Southern blot analysis of LB and LBC cells. DNA
(10jIg) isolated from LB (lane 1), LBC (lane 2) and normal
BALB/c splenocytes (lane 3) were digested with BamHI, HindlIl
and EcoRI, electrophoresed through a 1% agarose gel and
transferred to a nylon membrane as described in Materials and
methods. Filters were hybridised with (a) I-Aad and (b) I-Afld
specific probes. PM, Molecular weight standard is k DNA
digested with HindlII.
Figure 3 Cell ELISA analysis of I-Ad molecule expression after
LBC I-Aad and I-Af1d genes transfer. Approximately 3 x 105 LBC,
LBCT cells or macrophages were seeded into wells and expression
of MHC class II molecules was analysed by ELISA as described
in Materials and methods. Results are shown as OD at 405nm
and represent the mean value +s.d. of triplicates. The absorbance
of the negative controls was < 0.005 in all cases. *The highest
I-A expressing clone.
A A r-
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identical morphology and growth kinetics to original LBC
cells, when 1 x 103 LBCT cells were injected they were
completely rejected in almost all the mice challenged (10/12
survivors/mice injected, Table I) and the DT50 of mice
injected with 1.0 x 106 LBCT cells was twice as much as the
DT50 for the mice injected with LBC cells (Figure 5). The
effect of I-A transfection on tumorigenesis is caused by de
novo expression of these molecules rather than the
transfection procedure itself since neo-control transfections
failed to alter tumorigenic properties.
In vivo induction of anti-tumour specific cytotoxic activity in
syngeneic mice
To determine whether immunisation with LBCT cells elicited
specific CTL, an in vitro cytotoxicity assay was used. Spleen
cells obtained from mice immunised either with LBC or
LBCT cells, as described in Materials and methods, were
cultured for 5 days and tested for their ability to lyse LBC
target cells, using a 5'Cr-release assay. As Figure 6 shows,
minimal cytolytic activity was detected upon priming with
LBC cells. Nevertheless, when transfected cells (LBCT) were
used to induce tumour-specific CTL, response was enhanced
by 80% (14+1.2% with spleen cells from LBCi primed mice
vs 27+2% with splenocytes from LBCTi primed mice).
Similar specific cytotoxic response was induced in mice that
survived the challenge with transfected cells (LBCT). The
Figure 4 Cytofluorimetric analysis of IA molecule expression.
LBC and LBCT cells were incubated with MKD6 monoclonal
antibody or isotype-matched followed by goat anti-mouse FITC.
(a) LBCT cells compared with LBC cells. (b) LBCT cells. (c)
Negative control.
response was specific for tumour cells as BALB/c Con A
lymphoblasts were not lysed above control levels (data not
shown). Spleen cells from non-immunised mice were used as
controls for NK activity and invariably rendered less than
2% lysis. Controls for CTL activity were performed in vitro
by inducing allogenic CTL [splenocytes from BALB/c mice
immunised in vivo with LBCTi cells and sensitised in vitro
with irradiated Swiss splenocytes as shown in Figure 6 Sp
(Swiss); error bar].
Discussion
In this work we have reported the induction of MHC class II
molecule expression in an LBC tumour cell line (MHC class
II negative) and studied the effects on both immunogenicity
and tumour cell growth.
Hybridisation with probes specific for I-Aa and I-A,B genes
showed neither polymorphism nor aberrations, thus ruling
out pre-existing gene abnormalities. Consequently, INFy was
used to induce the expression of MHC class II molecules.
Induction of I-A molecules on either LB or LBC cells could
not be achieved by INF-,y treatment, in contrast to what has
been described for myeloid leukaemias (Lindahl et al., 1974).
These results are in agreement with recent research which
showed that INF-y is incapable of inducing the expression of
class II molecules on murine T lymphocytes, at variance with
what occurs in human or rat T lymphocytes (Glimcher and
Kara, 1992). The lack of an INF-y-mediated effect on class II
expression on either LB or LBC cells may indicate that
alterations have taken place in IFN receptor expression. In
our case, the fact that INF-,y treatment inhibited cell
proliferation (data not shown) suggests that these cells
express intact receptors for this cytokine.
In order to induce neo-expression of I-Ad molecules, LBC
u) ao
CA
0)
a)
L-
Days after challenge
Figure 5 Tumour challenge experiments. Groups of 6 BALB/c
mice were injected i.p. with 106 LB (x), LBC (0) or LBCT (A)
cells per mouse. Data were analysed by log-rank test, and are
representative of three independent experiments performed with
similar results.
Table I LBC and LBCT cell growth in BALB/c mice
Expression of No. ofsurvivors/No.
Tumour cells Injection dose I-Ad molecules ofmice infected
LBC 1.0x 103 0/12
LBC 1.0x 106 0/12
LBCT l.Ox 103 + 10/12a
LBCT 1.0x 106 + 2/12a
BALB/c mice were injected intraperitoneally and tumour growth was observed. aTumourfree mice
were observed up to 6 months after cell innoculation
0MHC gene transfection and anti-tumour immunity
C Mongini et a!
30
0 ob
.v
0
Is
10/1 20/1 40/1 80/1 120/1 40/1
Effector/target ratio
Figure 6 Anti-tumour CTL activity induced by LBCi and LBCi
cells. Spleen cells were isolated 7 days after final immunisation
with LBCi or LBCTi cells and cultured as described in Materials
and methods. Values represent the mean of triplicate cul-
tures+s.d. Data are representative of three independent
experiments performed with similar results. Positive controls
were performed in vitro by inducing allogeneic CTL co-culturing
irradiated Swiss splenocytes and spleen cells obtained from
BALB/c mice immunised with LBCi cells (error bar). *, Sp
(LBCi) x LBC; 0, Sp (LBCTi) x LBC; 0, Sp (LBCTi) x LBC;
_, Nsp x LBC. LZ, Sp (SWISSi) x SWISS.
cells were transfected with I-ACXd and I-Af3d genes. A low
number of clones was obtained and the LBCT cell clone
(which expressed the highest level of I-Ad antigens) was
chosen to evaluate the role played by I-Ad molecules in
oncogenesis and host resistance. The number of clones
obtained correlated with that described by other authors
(James et al., 1991) for experimental models using a triple
transfection, similar to the one we employed. In our case
three plasmids, two corresponding to each one of the two
chains that form the MHC class II molecule, and the
remaining one carrying the gene that confers resistance to the
antibiotic neomycin, were introduced. The expression of both
chains on transfected cells was corroborated by using the
monoclonal antibody MKD6, that recognises the complete
I-A molecule (Kappler et al., 1981).
LBCT cells (I-A+) showed identical morphology and in
vitro growth kinetics as the parental LBC cells (I-A-).
However, it is worthwhile pointing out that when transfected
cells were inoculated in syngeneic mice (1.0 x 103LBCT cells
per mouse) they failed to induce tumour growth, in contrast
to LBC cells that did so, and the DTso for mice injected with
a large inoculum (1.0 X 106 LBCT cells per mouse) was three
times the value for mice injected with the original cell line.
Controls performed transfecting only Neo gene did not
express I-Ad molecules and failed to alter tumorigenic
properties indicating that the transfection procedure itself is
not responsible for preventing tumour growth.
The major role of the immune system in the survival time
increase of mice inoculated with LBCT cells was established
through studies on specific cytotoxic induction. The
significant enhancement of specific CTL response found in
mice immunised with irradiated LBCT cells or inoculated
with living LBCT cells, when compared with that induced by
LBC cells (27+2% vs 14+1.2%), indicated that cellular
immunity is a crucial mechanism associated with the
prevention of tumour growth found in mice challenged with
LBCT cells. Humoral immune response induced in syngeneic
mice immunised with LBCT cells remained unchanged in
comparison with that obtained by the immunisation of mice
with LBC cells (data not shown), suggesting that the increase
in survival time recorded for mice inoculated with LBCT cells
could hardly be caused by effector mechanisms of the
immune system involving antibodies, such as the antibody-
mediated cellular cytotoxicity or complement fixation.
Strikingly, the weak immunogenicity induced by LBC cell
line (Mongini et al., 1995) which derived from a non-
immunogenic, aggressive tumour of spontaneous origin
(Ruggiero et al., 1984; Alvarez et al., 1989), in common
with most human tumours, was considerably enhanced by
transfecting LBC cells with I-Aad and I-Afld genes. On the
contrary, in the model systems described so far, complete
tumour rejection was achieved even though a large amount of
neoplastic cells were inoculated after priming with tumour
cells transfected with class II molecules (Ostrand-Rosemberg
et al., 1990; James et al., 1991; Baskar et al., 1994, 1995).
Nevertheless, in these cases, tumour cells were already
immunogenic in their syngeneic host, as derived from virus
or chemically induced tumours, and the level of immunity
generated with live transfected tumour cells might also be
induced by non-transfected irradiated tumour cells alone as
happens with some tumour cells engineered to secrete
cytokines (Moudgil and Sercarz, 1994). In our experimental
model, a low number of different epitopes that stimulate anti-
tumour response are restricted to a few molecules (Mongini
et al., 1994). Therefore, we suggest that the enhancement
achieved in cellular immune response seems quantitative
rather than qualitative, owing to clonal expansion of specific
cytotoxic T lymphocytes and as a result of lymphokines
synthesised by helper T lymphocytes that were stimulated
directly by the tumour itself.
Concerted action by CD4+ and CD8+ T cells in
successfully killing tumour cells has been demonstrated by
gene transfection of neoplastic cells leading to the release of
diverse helper cytokines (Fearon et al., 1990; Pardoll, 1993;
Golumbek et al., 1991; Pippin et al., 1994). Although a
tumour may succeed in generating a cellular response,
ineffective mechanisms of MHC class II restricted presenta-
tion may not allow anti-tumour effector cells to activate and
reach the critical number required for eradication of the
tumour. Recognition of tumour-specific peptides presented
on MHC class I molecules by CD8+ cells, and signals
generated by such recognition, may be insufficient to activate
precursor CTL cells. One of the additional signals necessary
for complete activation of T cells is triggered by lymphokines
produced by CD4+ helper T cells, which usually recognise
antigenic peptides presented on MHC class II by antigen
presenting cells such as macrophages or dendritic cells. The
expression of MHC class II molecules on LBCT cells allows
for direct presentation of class II restricted tumour-specific
antigens to helper T cells, which could provide the required
help for complete activation exerted by cytotoxic T cells.
Furthermore, direct participation of CD4+ lymphocytes in
cellular cytotoxic mechanisms restricted by MHC class II
molecules (Jacobson et al., 1984; McKisic, et al., 1991;
Dadmarz et al., 1995) led us to hypothesise on the
intervention of these lymphocytes in conjunction with
CD8+ on direct tumour cell lysis.
Our findings suggest that the induction of class II antigens
expression provides an effective method to achieve an
immunosurveillance status in cases where tumour cell
number is low and metastasis is liable to develop after
removal of the primary lesion. Further research may validate
such specific immunotherapy as a complement to surgical
treatment.
Abbreviations
LB, T cell leukaemia originating in a BALB/c mouse. LBC, cell
line derived from LB leukaemia; LBCT, LBC cells transfected with
I-Ad genes; LBCi, irradiated LBC cells, LBi irradiated LB cells;
LBCTi, irradiated LBCT cells; BSA, bovine serum albumin; TBS,
Tris-buffer saline; FCS, fetal calf serum; TBS-T, TBS containing
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sulphate; TBS-C, TBS containing non-fat dry milk; TBS-C, TBS
containing non-fat dry milk and Tween 20; DT5o, represents time
when 50% of challenged mice died; Sp (LBCi), splenocytes from
BALB/c mice immunised with LBCi cells; NSp, normal spleen
cells; Sp (LBCTi), splenocytes from BALB/c mice immunised with
LBCTi cells; Sp (SWISSi), splenocytes from BALB/c mice
immunised with LBCTi cells and sensitised in vitro with Swiss
splenocytes; CMC, cell-mediated cytolytic response; CTL, cyto-
toxic T lymphocytes.
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